Revolution Medicines, Inc.
RVMD
$39.13
$0.010.03%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 23.95% | 1,087.88% | |||
| Gross Profit | -23.95% | -1,087.88% | |||
| SG&A Expenses | 17.75% | 10.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.10% | 12.17% | |||
| Operating Income | -23.10% | -12.17% | |||
| Income Before Tax | -24.98% | -17.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.49% | -17.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.49% | -17.30% | |||
| EBIT | -23.10% | -12.17% | |||
| EBITDA | -23.27% | -12.37% | |||
| EPS Basic | -19.55% | -16.10% | |||
| Normalized Basic EPS | -20.00% | -16.12% | |||
| EPS Diluted | -19.55% | -16.10% | |||
| Normalized Diluted EPS | -20.00% | -16.12% | |||
| Average Basic Shares Outstanding | 4.14% | 1.03% | |||
| Average Diluted Shares Outstanding | 4.14% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
